Abstract A 31-year-old male patient developed an ulcer on the glans penis that evolved for three months without healing. We diagnosed it as leishmaniasis using polymerase chain reaction. No immunosuppression or associated diseases were observed. The patient was treated with meglumine antimoniate that cur...
Abstract In this study, we present two cases of cutaneous leishmaniasis in patients with end-stage renal disease, who were treated solely with intramuscular pentamidine. In such cases, treatment implies a fine line between therapeutic efficacy and toxicity. This is suggestive of a knowledge gap; however,...
Abstract INTRODUCTION: The drugs currently available for leishmaniasis treatment have major limitations. METHODS: In vitro and in vivo studies were performed to evaluate the effect of a quinoline derivative, Hydraqui (7-chloro-4-(3-hydroxy-benzilidenehydrazo)quinoline, against Leishmania amazonensis. I...
Genes associated with wound healing have been shown to be risk factors for cutaneous leishmaniasis (CL) which is caused by Leishmania braziliensis. In this study, we examined whether the genes previously associated with CL influenced the clinical outcome. Patients were genotyped and retrospectively class...
Antimonio/uso terapéutico,
Antiprotozoarios/uso terapéutico,
Estudios de Casos y Controles,
Predisposición Genética a la Enfermedad,
Genotipo,
Leishmaniasis Cutánea/tratamiento farmacológico,
Leishmaniasis Cutánea/genética,
Leishmaniasis Cutánea/patología,
Persona de Mediana Edad,
Polimorfismo de Nucleótido Simple,
Estudios Retrospectivos,
Pruebas Cutáneas,
Cicatrización de Heridas/genética
BACKGROUND Metformin (MET) is a hypoglycemic drug used for the treatment of diabetes, despite interference in host immunity against microorganisms. Cutaneous infection caused by pathogens such as Leishmania braziliensis (Lb), the agent responsible for cutaneous leishmaniasis (CL) in Brazil, represents a...
Abstract INTRODUCTION: Leishmaniasis, a disease caused by a parasite endemic to large areas of tropical and subtropical countries, is a growing public health problem. METHODS: Male BALB/c mice were infected with Leishmania amazonensis and treated with extracts isolated from Annona mucosa. RESULTS: ...
La histoplasmosis y la leishmaniasis son enfermedades olvidadas, endémicas en Argentina, y generalmente se asocian a inmunocompromiso. Presentamos el caso de un varón de 16 años, inmunocompetente, con histoplasmosis del sistema nervioso central y leishmaniasis cutánea. Inicialmente, el paciente prese...
Antibacterianos/administración & dosificación,
Antifúngicos/administración & dosificación,
Infecciones Fúngicas del Sistema Nervioso Central/complicaciones,
Infecciones Fúngicas del Sistema Nervioso Central/diagnóstico,
Infecciones Fúngicas del Sistema Nervioso Central/tratamiento farmacológico,
Histoplasmosis/complicaciones,
Histoplasmosis/diagnóstico,
Histoplasmosis/tratamiento farmacológico,
Inmunocompetencia,
Leishmaniasis Cutánea/complicaciones,
Leishmaniasis Cutánea/diagnóstico,
Leishmaniasis Cutánea/tratamiento farmacológico
Abstract: Pentavalent antimonials are the first-line drug treatment for American tegumentary leishmaniasis. We report on a patient with chronic renal failure on hemodialysis who presented with cutaneous lesions of leishmaniasis for four months. The patient was treated with intravenous meglumine under str...
Anfotericina B/uso terapéutico,
Antiprotozoarios/efectos adversos,
Antiprotozoarios/uso terapéutico,
Brasil,
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos,
Leishmaniasis Cutánea/complicaciones,
Leishmaniasis Cutánea/tratamiento farmacológico,
Leishmaniasis Cutánea/patología,
Antimoniato de Meglumina/efectos adversos,
Diálisis Renal,
Insuficiencia Renal Crónica/complicaciones
Abstract: Disseminated leishmaniasis is a severe and emerging form of American tegumentary leishmaniasis. Disseminated leishmaniasis is defined by the presence of more than 10 polymorphic cutaneous lesions, distributed over more than two noncontiguous parts of the body. Nasal mucosal involvement is obser...
